Mabtech has entered into a strategic collaboration with Sai Life Sciences to strengthen access to next-generation immunology solutions in the United States.

Under the agreement, Sai Life Sciences’ Boston discovery laboratory will function as a co-marketed execution and demonstration hub for Mabtech’s EYRA multiplex immunology platform. The collaboration aims to provide advanced immunology assay services, including high-sensitivity multiplex cytokine profiling and custom panel development, to biopharma and biotech companies.

The initiative is expected to accelerate the adoption of cutting-edge immune profiling technologies across research areas such as immuno-oncology, vaccines, inflammation and cellular therapy. By integrating the EYRA platform into Sai’s Boston site, both companies seek to bring scalable and efficient immunology workflows closer to discovery-stage research.

The EYRA platform, developed by Mabtech, addresses limitations of traditional flow-based and plate-based immunoassays by enabling simultaneous detection of multiple analytes in a single run. With features such as minimal hands-on time, automation readiness and intuitive software, the system is designed to streamline both routine and complex immune profiling studies.

Through this partnership, Mabtech’s assay expertise will be combined with Sai Life Sciences’ translational research capabilities, enabling researchers to generate reliable and decision-ready data earlier in the drug development process.

As part of the collaboration, the companies will jointly conduct business development activities targeting U.S.-based biopharma and biotech firms, with a focus on immuno-oncology, vaccine immunogenicity and inflammation programmes. The partnership will also include co-branded thought leadership initiatives, such as case studies, white papers and scientific presentations at key industry conferences.

Key components of the collaboration include the installation and operation of the EYRA platform at Sai’s Boston site, joint delivery of multiplex immunology assays and custom panels, client demonstrations and pilot programmes, as well as shared scientific publications and research initiatives.

The move underscores a broader effort by both companies to enhance access to advanced immunology tools and support faster, data-driven decision-making in early-stage drug discovery and translational research.